AMO Pharma Reports Positive Data from Investigator-Led TIDE Study of AMO-02 in Autism Spectrum Disorder

Treatment associated with improvement in social withdrawal, repetitive behaviors, daily living skills, memory and sleep quality LONDON and DURHAM, North Carolina, Oct. 29, 2018 /PRNewswire/ -- AMO Pharma Limited ("AMO Pharma"), a privately held biopharmaceutical company...

from PR Newswire: //https://ift.tt/2qiem2f